Search
Search Results
-
Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma
The longitudinal transition of phenotypes is pivotal in glioblastoma treatment resistance and DNA methylation emerged as an important tool for...
-
Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
Background and ObjectiveGlioblastoma is a cranial malignant tumor with a high recurrence rate after surgery and a poor response to chemoradiotherapy....
-
MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis
BackgroundMRI treatment response assessment maps (TRAMs) were introduced to distinguish recurrent malignant glioma from therapy related changes....
-
Whole genome sequencing in (recurrent) glioblastoma: challenges related to informed consent procedures and data sharing
Increased use of whole genome sequencing (WGS) in neuro-oncology for diagnostics and research purposes necessitates a renewed conversation about...
-
Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?
PurposeAngiogenesis plays a key role in glioblastoma, but most anti-angiogenic therapy trials have failed to change the poor outcome of this disease....
-
Exploration of biomedical knowledge for recurrent glioblastoma using natural language processing deep learning models
BackgroundEfficient exploration of knowledge for the treatment of recurrent glioblastoma (GBM) is critical for both clinicians and researchers....
-
Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma
PurposeNo standard treatment has yet been established for recurrent glioblastoma (GBM). In this context, the aim of the current study was to evaluate...
-
Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study
PurposeGlioblastoma is a malignant and aggressive brain tumour that, although there have been improvements in the first line treatment, there is...
-
Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma
PurposeRegorafenib is a multikinase inhibitor, approved as a preferred regimen for recurrent glioblastoma (rGB). Although its effects on prolonging...
-
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma
BackgroundBevacizumab (BEV), at a standard dose of 10 mg/kg every 2 weeks is associated with prolonged progression-free survival (PFS) but no...
-
Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution
BackgroundMultiple treatment options at glioblastoma progression exist, including reintervention, reirradiation, additional systemic therapy, and...
-
Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme
PurposeRecurrent glioblastoma is universally fatal with limited effective treatment options. The aim of this phase 2 study of Border Zone SRS plus...
-
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition
PurposeAfter glioblastoma (GB) recurrence, prognosis is very cumbersome. Therefore, health-related quality of life (HRQoL) and neurocognitive...
-
Stereotactic radiosurgery versus combined stereotactic radiosurgery and bevacizumab for recurrent glioblastoma; a systematic review and meta-analysis of survival
Recurrent glioblastoma (rGBM) is a brain tumor that is resistant to standard treatments. Although stereotactic radiosurgery (SRS) is a non-invasive...
-
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers
BackgroundThe optimal management strategy for recurrent glioblastoma (rGBM) remains uncertain, and the impact of re-irradiation (Re-RT) on overall...
-
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
PurposeWhile immune checkpoint inhibitors (ICI) have had success with various malignancies, their efficacy in brain cancer is still unclear....
-
Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis
BackgroundTumor-treating fields (TTF) is a novel cancer treatment that uses alternating electric fields to interfere with tumor cell mitosis. It has...
-
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma
PurposeThe prognosis of recurrent glioblastoma (rGBM) is poor, and there is currently no effective treatment strategy. Sonodynamic therapy (SDT) is a...
-
Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
BackgroundFor recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive...
